London WITHIN a short time of the introduction of cortisone ten years ago, it became clear that certain undesirable side-effects were associated with the administration of this compound. It was also clear that the incidence and severity of these side-effects were related in part to the dosage and duration of treatment, and in part to the individual response of the patient. It would be wrong to call most of these undesirable occurrences by any other name than side-effects. They should not be termed toxic because they are not the result of some toxic action but are the consequence of an increased blood level of corticosteroid hormone and some appear with equal readiness in patients with naturally occurring Cushing's syndrome. Although many different side-effects have been described, those of particular importance and consequence are: (1) Hypertension, (2) sodium retention and the formation of cedema, (3) potassium depletion, (4) osteoporosis and nitrogen depletion, (5) the development or accentuation of diabetes, and (6) peptic ulceration with hlmatemesis, melhna or perforation.
The first two of these side-effects are probably related, and the hypertension is largely dependent upon sodium retention. Osteoporosis has been attributed, according to the current orthodox view based on the work of Albright, to the anti-anabolic effect of corticosteroids on protein synthesis. However, recent work suggests that bone demineralization and collapse of vertebre may be as much due to disturbances of calcium and phosphorus metabolism as to protein synthesis. Diabetes mellitus usually occurs in patients who already have a tendency to diminished glucose tolerance and it is doubtful if frank diabetes develops in patients with previously normal carbohydrate metabolism. Indeed Fajans and Conn (1954) have evolved a most useful test using a single dose of cortisone to uncover latent diabetes.
Matters might have rested in this relatively unsatisfactory state had it not been for the organic chemists who suspected that by altering NovEMBER the structure of the cortisone molecule they might influence its biological properties. The first product of these researches to become commercially available was hydrocortisonethe naturally occurring adrenal glucocorticoid secreted by the human adrenal and the substance to which cortisone is converted in the body.
,=o Hydrocortisone
Although hydrocortisone proved slightly more potent than cortisone, there were no differences in the side-effects produced by the two compounds.
Fluorohydrocortisone.-The first major change in the biological properties of cortisone and hydrocortisone was effected by Fried May 26, 1959 May 26, (1953 May 26, , 1954 . They substituted a halogen atom in the 9-alpha position of the steroid molecule, and the most potent substance proved to be the fluorinated derivative of hydrocortisone. This was some ten times more potent, on a weight-forweight basis, than cortisone in the liver glycogen deposition test-a function which seems to run closely parallel to the anti-inflammatory action of the compound. However, fluorination also increased the sodium-retaining properties of the compound to a remarkable and disproportionate degree, with the result that fluorohydrocortisone proved 100 times more potent than the parent substance in its mineralocorticoid action. Despite its enhanced antiphlogistic potency, the extreme electrolyte activity of fluorohydrocortisone precluded its systemic use as a substitute for cortisone, although it has proved most useful in the topical treatment of dermatological and ophthalmic diseases. However, its main place is as the ideal substitute for parenterally administered deoxycortone in the treatment of adrenal insufficiency (Bayliss, 1958) . Many patients who have been adrenalectomized for the treatment of Cushing's disease, or for the arrest of malignancy, remain apparently well on substitution with cortisone alone, but often clinical manifestations of sodium depletion or biochemical abnormalities (a low serum sodium level and sometimes also hypochloremia and hyperkalkmia) occur even though supplements of sodium chloride are given (Bayliss, 1958; Nabarro and Walker, 1957) . These patients are immeasurably improved by the addition of a small dose of fluorohydrocortisone. The amount given must be sufficient to maintain a normal serum sodium level and not so great as to induce cedema or hypertension, although it should be remembered that in older patients the "normal" blood pressure may be greater than 120/80 and the patient feels better when the blood pressure is maintained at 150/90 mm.Hg. The usual dose required is 01 mg. daily or on alternate days, and the exact amount can only be determined by clinical experimentation.
Prednisolone and prednisone.-The next major change effected by the chemists was the introduction of a double bond between the first and second carbon atoms in the A ring of the steroid molecule. The resulting compounds, prednisone and prednisolone, derived respectively from cortisone and cortisol (hydrocortisone), proved to be four or five times more potent in glycogen deposition and antiphlogistic activity without any enhancement of mineralocorticoid activity. Thus the side-effects of sodium retention, potassium depletion, and hypertension-except when unusually large doses were given-were largely but not completely eliminated, and this constituted a major advance. Except in the treatment of adrenal insufficiency, prednisone and prenisolone came to replace cortisone and cortisol. But although the bugbear of cedema and hypertension had in large measure been eliminated, the other side-effects continued, with peptic ulceration and osteoporosis as the most important and troublesome.
Prednisolone
Chemists continued to synthesise new compounds and such is the structure of the steroid molecule that innumerable permutations and combinations are possible although often difficult to achieve technically. The goal of this effort has been to achieve a compound with "pure" anti-inflammatory activity dissociated from anti-anabolic and ulcerogenic properties. Each compound has to be obtained in an uncontaminated state and then subjected to a long series of animal tests to determine its biological properties.
Triamcinolone.-The next development involved altering the steroid molecule at the C-16 position, and triamcinolone which is 9-a-fluoroprednisolone with a hydroxyl group at C-16 was introduced. The hydroxylation considerably changed the properties of the 9-a-fluoroprednisolone which thereby lost its mineralocorticoid activity. Triamcinolone has been widely acclaimed for its antiphlogistic activity and has been used in situations previously treated with prednisone or prednisolone. It was hoped that the incidence of side-effects would be reduced, but these hopes have not been fulfilled. In potency triamcinolone is only slightly more powerful than the Al-steroids and 4 mg. is usually equivalent to 5 mg. prednisone or prednisolone (Heilman et al., 1957) . However, dyspepsia, perforation of a peptic ulcer and osteoporosis may occur (Hollander, 1957; Hart et al., 1958; Kendall and Hart, 1959; Thompson, 1959) , and a series of additional and unusual 90 930 Section of side-effects have been reported which are largely peculiar to triamcinolone, and seen only very rarely with other corticosteroids. These comprise joint pains, postprandial flushing, drowsiness, headache, loss of weight, muscular weakness particularly in the legs, and muscular wasting Hollander, 1957; Wells, 1958; Kendall and Hart, 1959) . The muscle weakness may be severe, and electromyography indicates a muscle-fibre lesion; the condition is not due to potassium depletion or to increased protein catabolism (Williams, 1959) . The cause of this disturbance, which is usually reversible when triamcinolone is stopped and another steroid substituted, is uncertain. It has been reported after unusually large doses of 9-afluorohydrocortisone and therefore attributed to the presence of a fluorine atom in the steroid molecule (MacLean and Schurr, 1959) . However, Harman (1959) has observed a similar myopathy in patients treated with prednisolone, and Ellis (1956) has produced necrosis of skeletal muscle in rabbits by giving massive doses of cortisone. This side-effect is particularly likely to occur if CHI2H I Triamcinolone the dose of triamcinolone exceeds 10-12 mg. daily, which may be necessary for the control of otherwise fatal conditions such as disseminated lupus erythematosus. Weight loss is also common during triamcinolone administration (Robinson and Robinson. 1959) , and may be progressive and marked. These changes occur sufficiently frequently to make triamcinolone less therapeutically useful than was initially hoped. In individual cases it may prove therapeutically superior to the Al-steroids but on the whole it is wiser to use prednisone and prednisolone, except in hypertensive patients and those who have developed aedema or hypertension with other corticosteroids (Thompson, 1959) .
6-methylprednisolone.
Methylprednisolone was the next corticosteroid to be introduced.
It differs from prednisolone in having an additional methyl group at the C-6 position. In potency it is about equivalent to triamcinolone and 4 mg. usually has an antiphlogistic effect 6-methylprednisolone equal to 5 mg. prednisolone. However, it does not appear to share with triamcinolone the peculiar side-effects of muscle weakness and weight loss. On the other hand no clear superiority over prednisolone has been demonstrated with regard to other side-effects although it may have less effect on electrolyte balance.
Dexamethasone.-The latest addition to the synthetic corticosteroid drugs is dexamethasone which is 9-a-fluoroprednisolone with a methyl group at the C-16 position (Arth, Johnston, et al., 1958; Arth, Fried, et al., 1958) . It is there-CH2OH =0 OH ) OH F CH3 Dexamethisone fore similar to triamcinolone but differs from it in having a methyl instead of a hydroxyl group added in the D-ring. However, this change has considerably altered the biological potency of the compound, and in its anti-inflammatory effect 0 75 mg. dexamethasone is equivalent to 5 mg. prednisolone or 4 mg. triamcinolone or 931 r Me6.,.
i methylprednisolone (Boland, 1958a) . Thus on a weight basis dexamethasone is the most potent corticosteroid available and its enhanced antiphlogistic activity is wholely dissociated from any electrolyte effect. For example, Addisonian patients satisfactorily maintained on cortisone rapidly develop symptoms and signs of sodium depletion when switched to dexamethasone. Clinical experience confirms that sodium retention, cedema and hypertension do not occur. Nor does dexamethasone appear to cause mental depression or euphoria. Unlike triamcinolone, it has not been observed to cause muscle weakness, muscular wasting, and loss of weight (Boland, 1958b) . Some experimental works suggest that dexamethasone does not reduce carbohydrate tolerance as readily as other corticosteroids (Bunim et al., 1958; Villa et al., 1958) . However, dexamethasone induces many of the same side-effects as prednisolone, such as facial mooning, buffalo hump, hypertrichosis and ecchymotic skin lesions. It has a distinct tendency to enhance appetite with a consequent increase in weight particularly marked on the abdomen. Peptic ulceration and dyspepsia occur in about the same frequency as after prednisolone.
Satisfactory results in the treatment of rheumatoid arthritis have been reported by various workers and in some instances the control of the disease has been better with dexamethasone than with prednisolone (Boland, 1958b; Robecchi et al., 1959) .
Metabolic studies have confirmed that dexamethasone does not cause sodium retention; it may even induce a sodium diuresis. Potassium excretion is not increased (Bunim et al., 1958) . It may, however, increase nitrogen excretion particularly when large doses are given. Loss of phosphorus and calcium also occurs (Bunim et al., 1958; Slater et al., 1959; Bayliss and Zilva, 1958, unpublished observations) . Much of the increased excretion of calcium is found in the faeces, and this is an unusual finding not observed with other corticosteroids. It suggests that skeletal disorders may be induced during prolonged treatment with dexamethasone. Since the increased loss of calcium is mainly fecal it occurred to us that this effect might be reversed by co-administration of vitamin D. Experimentally there is some evidence to support this, and there is some additional evidence that administration of vitamins A and D together is more effective than vitamin D alone.
The problem of peptic ulceration still remains. It is perhaps surprising that after a decade of corticosteroid therapy, there is no unanimity of opinion as to whether this ulcerogenic effect is due to a local action on the gastric mucosa or is a humoral effect. Certainly peptic ulceration is not, in my experience of more than 40 patients, a common occurrence in Cushing's syndrome, and many rheumatologists have found that the co-administration of antacids may reduce the incidence of dyspepsia. Some have suggested that corticosteroids should be administered as an emulsion. Recently trials have been started using enteric-coated tablets and preliminary results are promising.
